• Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. AKBA Stock Summary.  Peer Grade Following up on its announcement of positive data in May, Akebia Therapeutics (AKBA) announces mixed final results from two open-label Phase 3 clinical trials, PRO2TECT-CONVERSION and PRO2TECT-CORRECTION, evaluating vadadustat in adult chronic kidney disease patients with anemia not on dialysis.Both studies met the primary and key secondary efficacy endpoints demonstrating non-inferiority... Akebia Therapeutics Inc said on Thursday its experimental drug to treat anemia due to chronic kidney disease in patients not on dialysis failed to meet the main safety goal in a late-stage trial, sending its shares down 70%. Stock Advisor launched in February of 2002. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. Earnings were up 193.99%, but Akebia Therapeutics still reported an overall loss of $173.82 million. Note: Calculations may not appear exact due to rounding. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from … The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. In Q1, Akebia Therapeutics brought in $88.48 million in sales but lost $59.12 million in earnings.What Is Return On Capital Employed • 4 Stay-at-Home Stocks to Buy as Coronavirus Cases Surge, • 2 Little-Known Electric Vehicle Stocks That Could Offer Massive Gains, • 2 Travel Stocks to BUY in December, 2 to AVOID. Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news and financial information from CNBC. If You Had Bought Akebia Therapeutics (NASDAQ:AKBA) Stock A Year Ago, You Could Pocket A 132% Gain Today finance.yahoo.com - August 12 at 9:23 AM Akebia … Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. in Biotech. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. The options have an exercise price of $10.41 per share, which is equal to the closing price of Akebia's common stock on the grant date. Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investing decisions. Akebia Therapeutics. Earnings were up 193.99%, but Akebia Therapeutics still reported an overall loss of $173.82 million. Get today's Akebia Ther stock price and latest AKBA news as well as Akebia Ther real-time stock quotes, technical analysis, full financials and more. In Q1, Akebia Therapeutics brought in $88.48 million in sales but lost $59.12 million in earnings.What Is Return On Capital Employed. AKBA 3.39 0.09 (2.73%). Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -1.03% from its latest closing price compared to the recent 1-year high of $13.71. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is exp... Akebia Therapeutics ([[AKBA]] -0.2%) has initiated an investigator-sponsored study evaluating the use of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a potential therapy to prevent and lessen the severity of acute respiratory distress syndrome ((ARDS)), a complication of COVID-19 infection. To see all exchange delays and terms of use, please see disclaimer. View real-time stock prices and stock quotes for a full financial overview. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Akebia Therapeutics Stock Is Crashing Today @themotleyfool #stocks $AKBA, Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript, Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript, Why Akebia Therapeutics Stock Is Crushing It Today, 2 Small-Cap Stocks That Could Double Your Money, Copyright, Trademark and Patent Information. See you at the top! November 24, 2020. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Copyright © 2020. News. Shares were then crushed when it... Elle Investments on Seeking Alpha | September 22, 2020, This covered call strategy is an effective way to navigate an overbought market….TSLA. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. In Q2, Akebia Therapeutics (NASDAQ: AKBA) posted sales of $90.14 million. Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. CAMBRIDGE - Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the efficacy and safety of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in … Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity. Akebia and its partner, Japanese drugmaker Otsuka, plan to meet with the FDA before the end of 2020. A drug isn't likely to be approved by the FDA if there are concerns that it isn't safe. The results from an earlier phase 3 trial of the drug in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis were overwhelmingly positive. Investment Thesis Summary Earlier this year, shares of Akebia Therapeutics (AKBA) surpassed $12.00/share on positive vadadustat data from the two phase 3 INNO2VATE trials for treating anemia due to dialysis-dependent ("DD") chronic kidney disease ("CKD"). Zacks Equity Research 10/13/2020 02:40 AM ET Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Why? Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 26, 2020 Akebia Therapeutics to Report Third Quarter 2020 Financial … The … • Investors: We Have Much to Be Thankful For! Just enter your email address below. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Find the latest news headlines from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. With a year-over-year growth in debt of 247.44%, Akebia Therapeutics Inc's debt growth rate surpasses 93.78% of about US stocks. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … AKBA Stock Analysis Overview . Market data powered by FactSet and Web Financial Group. Press Release reported on 11/18/20 that Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500(TM) AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. Akebia Therapeutics: The Drop From The Missed Safety Endpoint Offers A Good Reentry Point, Matching Downside Protection With Upside Potential in Akebia Therapeutics, The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study, Akebia down big after vadadustat misses safety endpoints in late-stage studies in CKD anemia, Akebia Therapeutics' anemia treatment fails to meet safety goal in late-stage study, Akebia launches vadadustat study in COVID-19 complication, Akebia Initiates Vadadustat Study In Covid-19 Patients, • 5 Stocks Setting Up for BIG MOVES in December. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership ... Akebia Therapeutics Inc is a biopharmaceutical company. While the experimental drug met the primary and secondary efficacy endpoints of the study, it didn't meet the primary safety endpoint. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Trade Grade  Buy & Hold Grade Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. CEO John Butler stated, "We believe the cardiovascular safety of vadadustat is supported by the totality of the data from our global Phase 3 program.". Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. In Q2, Akebia Therapeutics (NASDAQ: AKBA) posted sales of $90.14 million. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock.  Industry Rank, Ranked of 389 Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief Of Nephrology And Professor At Duke University School Of Medicine, To Board Of Directors By PR Newswire Apr 7, 2020 8:00 AM EDT CAMBRIDGE, Mass. Post-Market 0.02 (0.59%) ROCE Insights For Akebia Therapeutics. Vadadustat has been evaluated in two late-stage studies. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a late-stage study of vadadustat in treating anemia due to chronic kidney disease (CKD) in adult patients not on dialysis. Returns as of 12/01/2020. Let's conquer your financial goals together...faster. CAMBRIDGE, Mass., May 11, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to … Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 40, which is below average. Researching Akebia Therapeutics (NASDAQ:AKBA) stock? November 18, 2020. Akebia thinks that it has a shot at winning FDA approval for vadadustat in both dialysis and non-dialysis settings based on the combined data from both studies. It's not surprising that investors bailed on the biotech stock after the late-stage results were announced. The study will enroll up to... Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and … The post Akebia Initiates Vadadustat Study In Covid-19 Patients appeared first on Smarter Analyst . View today's stock price, news and analysis for Akebia Therapeutics Inc. (AKBA). Analysts have given the company’s stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10. The company’s stock price has collected 13.39% of gains in the last five trading sessions. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to … Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. However, Akebia said that it still plans to file for FDA approval of vadadustat. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The companies intend to submit for U.S. regulatory approval of vadadustat in the dialysis and non-dialysis indications "as early as possible next year.". … • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million.